서울대학교 중앙도서관
S-Space 소개
My S-Space
로그인이 필요합니다.
Login

S-Space

Browse

Publisher

Jump to a point in the index
Or type in a year

  • Sort by
  • In order
  • Results/Page
  • Authors/record

Showing results 1 to 40 of 68

Issue DateTitle / Author(s) / CitationFileAltmetrics
1997-07
Expression of transforming growth factor β type II receptor reduces tumorigenicity in human gastric cancer cells

Chang, Jay; Park, Keunchil; Bang, Yung-Jue; Kim, Won Seog; Kim, David; Kim, Seong-Jin

Cancer Research, Vol.57 No.14, pp.2856-2859

1999-02
Antiangiogenesis treatment for gliomas: Transfer of antisense vascular endothelial growth factor inhibits tumor growth in vivo
2000-06
The relevance of cell proliferation, vascular endothelial growth factor, and basic fibroblast growth factor production to angiogenesis and tumorigenicity in human glioma cell lines

Ke, L.D.; Shi, Y.-X.; Im, S.-A.; Chen, X.; Yung, W.K.A.

Clinical Cancer Research, Vol.6 No.6, pp.2562-2572

2001-06
Transcriptional silencing of Cyclooxygenase-2 by hyper-methylation of the 5′ CpG island in human gastric carcinoma cells
2003-01
Gastric Epithelial Reactive Oxygen Species Prevent Normoxic Degradation of Hypoxia-inducible Factor-1α in Gastric Cancer Cells
2004-06
Phase I and pharmacokinetic study of Genexol-PM, a cremophor-free, polymeric micelle-formulated paclitaxel, in patients with advanced malignancies
DOI
2004-08
Class I histone deacetylase-selective novel synthetic inhibitors potently inhibit human tumor proliferation
DOI
2004-09
Cyclooxygenase-2 and p53 expressions in endometrial cancer
2005-03
Cyclooxygenase-2 inhibits novel ginseng metabolite-mediated apoptosis
DOI
2005-09
Relative and absolute risks of cigarette smoking on major histologic types of lung cancer in Korean men

Yun, Young Ho; Lim, Min Kyung; Jung, Kyu Won; Bae, Jong-Myon; Park, Sang Min; Shin, Soon Ae; Lee, Jin Soo; Park, Jae-Gahb

CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION Vol.14 No.9, pp. 2125-2130

DOI
2006-04
Optimization of patient selection for gefitinib in non-small cell lung cancer by combined analysis of epidermal growth factor receptor mutation, K-ras mutation, and Akt phosphorylation
DOI
2006-07
High fluorodeoxyglucose uptake on positron emission tomography in patients with advanced non-small cell lung cancer on platinum-based combination chemotherapy
DOI
2006-12
Histone deacetylase inhibitor enhances 5-fluorouracil cytotoxicity by down-regulating thymidylate synthase in human cancer cells

Lee, Ju-Hee; Park, Jung-Hyun; Jung, Yeonjoo; Kim, Jee-Hyun; Jong, Hyun-Soon; Kim, Tae-You; Bang, Yung-Jue

Molecular Cancer Therapeutics, Vol.5 No.12, pp.3085-3095

DOI
2008-03
Combined lapatinib and cetuximab enhance cytotoxicity against gefitinib-resistant lung cancer cells

Kim, Hwang-Phill; Han, Sae-Won; Kim, Sung-Hak; Im, Seock-Ah; Oh, Do-Youn; Bang, Yung-Jue; Kim, Tae-You

Molecular Cancer Therapeutics, Vol.7 No.3, pp.607-615

DOI
2008-03
Enzastaurin, a protein kinase Cβ inhibitor, suppresses signaling through the ribosomal S6 kinase and bad pathways and induces apoptosis in human gastric cancer cells
DOI
2009-09
Combination of EGFR and MEK1/2 inhibitor shows synergistic effects by suppressing EGFR/HER3-dependent AKT activation in human gastric cancer cells
DOI
2010-03
An Adenoviral Vaccine Encoding Full-Length Inactivated Human Her2 Exhibits Potent Immunogenicty and Enhanced Therapeutic Efficacy without Oncogenicity
DOI
2011-03
ERCC1 and ERCC2 Polymorphisms Predict Clinical Outcomes of Oxaliplatin-Based Chemotherapies in Gastric and Colorectal Cancer: A Systemic Review and Meta-analysis
DOI
2011-07
Changes in Tumor Density in Patients with Advanced Hepatocellular Carcinoma Treated with Sunitinib
DOI
2012-02
Evaluation of the Antitumor Effects and Mechanisms of PF00299804, a Pan-HER Inhibitor, Alone or in Combination with Chemotherapy or Targeted Agents in Gastric Cancer
DOI
2013-01
STAT3-RANTES autocrine signaling is essential for tamoxifen resistance in human breast cancer cells
DOI
2013-01
Antitumor activity of saracatinib (AZD0530), a c-Src/Abl kinase inhibitor, alone or in combination with chemotherapeutic agents in gastric cancer
DOI
2013-06
RAD51C-Deficient Cancer Cells Are Highly Sensitive to the PARP Inhibitor Olaparib
DOI
2015-05
Molecular changes associated with acquired resistance to crizotinib in ROS1-rearranged non-small cell lung cancer

Song, Ahnah; Kim, Tae Min; Kim, Dong-Wan; Kim, Soyeon; Keam, Bhumsuk; Lee, Se-Hoon; Heo, Dae Seog

Clinical Cancer Research, Vol.21 No.10, pp.2379-2387

DOI
2015-06
Optimal patient selection for trastuzumab treatment in HER2-positive advanced gastric cancer
DOI
2016-05
Pan-cancer immunogenomic perspective on the tumor microenvironment based on PD-L1 and CD8 T-cell infiltration
DOI
2016-07
Src as a Therapeutic Target in Biliary Tract Cancer
DOI
2016-10
Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity
DOI
2017-01
HER2 Status in Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma for Entry to the TRIO-O13/LOGiC Trial of Lapatinib
DOI
2017-04
AZD6738, A Novel Oral Inhibitor of ATR, Induces Synthetic Lethality with ATM Deficiency in Gastric Cancer Cells
DOI
2017-06
Resistance Mechanism against Trastuzumab in HER2-Positive Cancer Cells and Its Negation by Src Inhibition

Jin, Mei Hua; Nam, Ah-Rong; Park, Ji Eun; Bang, Ju-Hee; Bang, Yung-Jue; Oh, Do-Youn

Molecular Cancer Therapeutics, Vol.16 No.6, pp.1145-1154

DOI
2017-10
A first-time-in-human study of GSK2636771, a phosphoinositide 3 kinase beta-selective inhibitor, in patients with advanced solid tumors
DOI
2017-10
Efficacy of sequential ipilimumab monotherapy versus best supportive care for unresectable locally advanced/metastatic gastric or gastroesophageal junction cancer
DOI
2018-06
Safety and antitumor activity of pembrolizumab in patients with estrogen receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer
DOI
2018-07
Change in topoisomerase 1–positive circulating tumor cells affects overall survival in patients with advanced breast cancer after treatment with etirinotecan pegol
DOI
2018-08
A first-in-human study of the new oral selective estrogen receptor degrader AZD9496 for ER+/HER2- advanced breast cancer
DOI
2018-12
nCirculating biomarkers and resistance to endocrine therapy in metastatic breast cancers: Correlative results from AZD9496 oral SERD phase I trial
DOI
2018-12
Androgen receptor inhibitor enhances the antitumor effect of PARP inhibitor in breast cancer cells by modulating DNA damage response
DOI
2019-02
Tumor-Associated Macrophages Enhance Tumor Hypoxia and Aerobic Glycolysis
DOI
2019-06
Phase I study of the indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor navoximod (GDC-0919) administered with PD-L1 inhibitor (atezolizumab) in advanced solid tumors
DOI
1 2